GHRP-6Interpret the evidence
What the 2026 COURAGE-2 stroke trial found about a specific combination
2 numbered sourcesSource years 2021, 2026
Peptides are short chains of amino acids held together by peptide bonds. Some carry signals that alter what cells do after a change in their environment. Growth hormone–releasing peptide 6, or GHRP-6, is a synthetic six-residue peptide that activates the ghrelin receptor and can stimulate growth hormone release. In 2026, a clinical trial reported whether a combination containing GHRP-6 improved disability after acute ischemic stroke. [1, 2]
An ischemic stroke occurs when blood flow to part of the brain is interrupted. The COURAGE-2 investigators asked whether adding two compounds, epidermal growth factor (EGF) and GHRP-6, to standard care could improve recovery. They randomized 188 adults in Cuba to receive the combination with standard care or standard care alone. The trial was open-label, meaning the people involved knew which group participants were assigned to. The main disability assessment used the modified Rankin Scale, which summarizes how much help a person needs with everyday activities after stroke. [1]
The full randomized population did not show a clear difference on the primary disability comparison. The investigators also found no overall difference on a separate measure of daily functioning or on survival. They reported signals favoring the treatment in a smaller group with more severe strokes. A subgroup signal can help define the question for a new trial, particularly when it involves relatively few people. Its estimate is less stable and needs confirmation in a study designed to examine that group. [1]
The full report also describes variation in the number of participants with severe stroke across the groups and more serious adverse events numerically in the treatment group, although the investigators classified none of those serious events as treatment related. The uncertainty around that comparison is important. The trial tested a specific two-compound intervention under hospital conditions and did not have a GHRP-6-only group or an EGF-only group. It therefore cannot tell which ingredient contributed to a signal or establish safety or effectiveness for GHRP-6 as a standalone intervention. [1]
This recent trial is direct human evidence about EGF plus GHRP-6 and a specific stroke outcome. The most informative result is the comparison across all randomized participants, for which the trial missed its primary endpoint. The smaller subgroup result supports a research question about stroke severity. It does not establish a clinical indication for the peptide by itself. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
